Karyopharm’s initial focus is on seeking the regulatory approval and commercialization of our lead drug candidate, selinexor (KPT-330), as an orally administered agent in cancer indications with significant unmet clinical need, initially for hematologic malignancies. We then plan to seek additional approvals for the use of selinexor in combination therapies to expand the patient populations that are eligible for selinexor, as well as to move selinexor further towards front-line cancer therapy. We are also advancing the clinical development of selinexor in multiple solid tumor indications and developing SINE™ compounds as a completely novel approach to treat cancers and other diseases in areas of unmet medical needs. Our goal is to foster scientific creativity with pioneering technologies and developmental approaches within an innovative culture that will accelerate first in class small molecule modulators of nuclear transport into effective chronic therapeutics for life threatening conditions.
We foster courage, urgency, resilience, energy, creativity and innovation in our employees and collaborators, recognizing the contributions of each to the success of the team. Integrity and respect are core to our success. We strive to benefit patients, physicians, employees, and shareholders by creating innovative medicines that improve the quality and duration of patients’ lives.